CAR-seet 01: A pilot study for diagnosing CRS and icans using wearable consumer devices

  • Publications
  • CAR-seet 01: A pilot study for diagnosing CRS and icans using wearable consumer devices
Year
2025
Type(s)
Author(s)
Shafagati, Nazila and Baker, Corey E and Wagner-Johnston, Nina and Smith, Douglas, Smith, B. Douglas and Ali, Syed Abbas and Salvatori, Mariana and Varadhan, Ravi and Imus, Philip and Sterling, Cole
Source
American Society of Hematology (ASH)
Url
https://doi.org/10.1182/blood-2025-2641
BibTeX
BibTeX
Background: Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies represent burgeoning treatment options in the hematologic malignancies and, more recently, solid tumor treatment landscapes. Unique toxicities associated with these therapies, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), necessitate frequent in-person monitoring at specialized medical centers with expertise in management and limit widespread deployment and access to these potentially life-saving therapies.
Methods: We designed the CAR-SEET (Chimeric Antigen Receptor Side Effect Evaluation Tool) Pilot Study to evaluate the feasibility and clinical utility of remote monitoring using a commercially available wearable device (Apple Watch) for the prediction and diagnosis of CRS. Primary aims included: 1) Feasibility- defined by the ability to obtain…